|
Outcomes at end of study (median time of 134 weeks) |
|||
| Data |
Immediate n = 24 |
Defer n = 19 |
P |
|
|
|||
| HIV-related illness |
|||
| No. patient (%) |
4 (16.7) |
- |
0.118 |
| Adverse events |
|||
| No. patient (%) |
22 (91.7) |
19 (100) |
0.495 |
| No. event (% per month) |
100 (13.3) |
97 (17.0) |
0.081 |
| ARV-related adverse events |
|||
| No. patient (%) |
7 (29.2) |
4 (21.1) |
0.728 |
| No. event (% per month) |
10 (1.3) |
5 (0.7) |
0.467 |
| Median weight for age Z-scores (IQR) |
-1.1 (-1.5 to -0.8) |
-1.0 (-1.7 to 0.2) |
0.525 |
| Median height for age Z-scores (IQR) |
-1.4 (-2.0 to -0.8) |
-0.8 (-1.3 to -0.4) |
0.171 |
| Median CD4% (IQR) |
31 (24 – 39) |
23 (17 – 31) |
0.032 |
| Median CD4% change (IQR) |
13.5 (4 – 18) |
3 (-2 to 13) |
0.012 |
| Median viral load*, log (IQR) |
1.7 (1.7 – 2.5) |
3.1 (1.7 – 4.5) |
0.039 |
| Median change viral load, log (IQR) |
-2.8 (-3.4 to -1.9) |
-1.8 (-3.2 to -0.3) |
0.079 |
| Median Hemoglobin, g/dL (IQR) |
11.7 (10.9 – 12.5) |
11.7 (10.9 – 12.5) |
0.961 |
| Median alanine transferase, unit/mL (IQR) |
15 (12.3 – 21.8) |
18 (14 – 23) |
0.418 |
| Median triglyceride, mg/dL (IQR) |
72 (46 – 109) |
98 (61 – 156) |
0.106 |
| Median cholesterol, mg/dL (IQR) |
158 (152 – 202) |
160 (143 – 180) |
0.197 |
| Median glucose, mg/dL (IQR) |
77 (67 – 87) |
76.5 (72.3 – 90.5) |
0.833 |
|
*Median viral load in the 10 deferred arm children who started ART was 1.7 log (IQR 1.7–1.7) which was similar to that in the immediate arm children (p = 0.58) | |||
Ananworanich et al. AIDS Research and Therapy 2008 5:24 doi:10.1186/1742-6405-5-24 |
|||